Heart Attack Risks Highlighted In Clinical Trials Cause Concern Following Invokana Lawsuit

March 18, 2016 – – TheProductLawyers.com reports on concerning results of clinical trials conducted on new-generation, type-2 diabetes drug Invokana. Trial results indicated that the SGLT2 class inhibitor drug seemed to significantly increase heart attack risks among patients using it; especially during the first 30 days of their treatment.

Invokana received approval from the U.S. Food and Drug Administration in 2013, and was the first of a brand new class of diabetes drugs called SGLT2 inhibitors to be released to the public. Clinical trials conducted on the drug showed multiple patients who quickly suffered from strokes or heart attacks–all within 30 days or less into their treatment regimens. Interestingly enough, after this 30 day seemingly high-risk period, the noted risks suddenly leveled out. Those conducting the clinical trials have yet to determine exactly why this occurs, but have stated that it may have to do with cholesterol levels in patients, which are known to be raised by diabetes drugs and potentially cause heart problems.

Although the FDA has recently released some public safety communications concerning the drug, and has asked manufacturer Janssen Pharmaceuticals (a division of Johnson & Johnson) to make some necessary changes to the product’s warning label, they have not yet addressed the heart attack issue, but rather other notable and potentially life-threatening side effects. In a recent article, The New York Times addressed the absence of heart attack warnings on the drug, stating, “The label of the drug includes no warnings about heart attacks or strokes. …The FDA is requiring Johnson & Johnson to conduct five post-marketing studies, including a clinical trial to determine more definitively if the drug increases those risks.”

As many await the results of these important post-market studies, medical professionals expressing concerns are requesting that all patients using Invokana or other similar SGLT2 class inhibitor drugs remain on the lookout for symptoms of oncoming heart attacks, specifically arm, neck, chest, jaw, and shoulder pain, dizziness, nausea, and vomiting, excess fatigue and sweating, or trouble breathing. Those using the drug are asked to watch for the signs especially within the first 30 days of their treatment, due to the clinical study findings. Patients who have even a few of these symptoms are being encouraged to seek medical attention immediately.

The attorneys of Banville Law are consistently working to keep the public informed of important information released on this drug and others. To better accomplish this, they sponsor TheProductLawyers.com, an online resource website filled with up-to-date information on Invokana and other drugs. They are also working to ensure that anyone who has taken Invokana or another SGLT2 class inhibitor drug and who has experienced health problems that they believe were caused by the drug will be provided with the important opportunity to evaluate their legal rights in full. These patients may be entitled to significant compensation through legal action. To help those looking to pursue justice in the matter, the attorneys of Banville Law are currently offering free legal consultations for affected parties.

To request additional Invokana lawsuit information, or to ask questions, please contact Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008774